查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1971853

大麻素药物发现与开发市场分析及预测（至2035年）：按类型、产品、服务、技术、应用、形式、最终用户、阶段、模式和功能划分

Cannabinoid Based Drug Discovery And Development Market Analysis and Forecast to 2035: Type, Product, Services, Technology, Application, Form, End User, Stage, Mode, Functionality
出版日期: | 出版商: Global Insight Services | 英文 408 Pages | 商品交期: 3-5个工作天内

价格
简介目录

预计到2034年，大麻素药物研发市场规模将从2024年的17.6亿美元成长至22.8亿美元，年复合成长率约为2.6%。该市场涵盖针对多种疾病的大麻素衍生药物的研究与开发。借助生物技术的进步，该市场探索大麻化合物的治疗潜力，重点关注疼痛管理、神经系统疾病和肿瘤治疗。不断变化的法规环境和人们对大麻治疗方法的日益认可正在推动创新，临床试验和安全性评估也日益受到重视，以满足严格的医疗标准。

受治疗应用相关研发投入不断成长的推动，大麻素药物发现和开发市场正经历强劲成长。製药领域处于领先地位，这主要得益于人们对大麻素疗法在疼痛管理和神经系统疾病治疗方面日益增长的兴趣。在该领域，合成大麻素凭藉其可控制的成分和可预测的疗效，占据主导地位。天然大麻素是成长第二快的细分市场，反映出人们对植物来源化合物的偏好日益增强。研发服务领域也展现出良好的成长前景，受託研究机构（CRO）在推动大麻素研究方面发挥着至关重要的作用。由于需要全面的安全性和有效性数据，临床前研究服务处于主导地位。临床试验服务是成长第二快的领域，这得益于大麻素疗法监管核准的不断增加。对奈米技术和经皮吸收贴片创新给药系统的投资进一步提升了市场潜力，并有望提高相关人员的盈利。

市场区隔
类型 合成大麻素，天然大麻素
产品 大麻二酚（CBD）、四氢大麻酚（THC）、大麻醇（CBG）、大麻酚（CBN）、大麻色烯（CBC）
服务 临床前研究、临床试验、法规咨询、药物製剂。
科技 高效液相层析（HPLC）、气相层析法（GC）、质谱法（MS）、核磁共振法（NMR）
目的 疼痛管理、神经系统疾病、肿瘤学、精神疾病
形式 片剂、胶囊、油剂、乳霜、吸入剂
最终用户 製药公司、研究机构、受託研究机构
步 药物发现、临床前试验、I期临床试验、II期临床试验、III期临床试验
模式 内部开发，外包开发
功能 镇痛、抗发炎、抗惊厥、神经保护。

市场概况：

大麻素药物研发市场正经历市场份额、定价策略和新产品上市方面的动态变化。各公司正利用创新製剂技术和策略联盟来巩固其市场地位。定价策略竞争日益激烈，反映出需要在价格可负担性和尖端研发成本之间取得平衡。在新兴市场，随着监管环境的改善和大麻素疗法分销管道的扩大，产品上市数量激增。这种环境为成长和创新提供了理想的条件。市场竞争日趋激烈，主要企业正凭藉先进的研发能力和多元化的产品系列争夺主导。监管影响至关重要，北美和欧洲严格的监管准则为产品核可和市场准入设定了高标准。与竞争对手的基准分析显示，临床试验和专利收购的投资趋势正在上升。该市场的特点是技术快速发展，因此，企业必须在创新和合规方面领先，才能维持竞争优势。

主要趋势和驱动因素：

受监管环境不断变化和大麻素疗法接受度日益提高的推动，大麻素药物的发现和开发市场正经历强劲增长。主要趋势包括：从慢性疼痛管理到神经系统疾病等众多医学领域，大麻素临床试验的数量都在增加。製药业正经历战略合作和联合研究的激增，旨在加速药物的发现和开发。推动这一成长的关键因素是对大麻素治疗潜力的日益认可，这促使研发投入不断增加。此外，生物技术和基因组学的进步使得大麻素药物的标靶化和製剂更加精准，进一步强化了这一趋势。各地合法化进程的推进正在扩大市场进入，并推动对创新治疗方法的需求。此外，随着慢性病盛行率的上升和人口老化，人们对新的治疗方案的需求日益增长，而大麻素被视为一种极具前景的替代疗法。对于能够驾驭复杂的法规环境并提供有效、安全且合规的大麻素治疗方法的公司而言，存在着许多机会。随着市场日趋成熟，预计将有巨大的成长潜力，尤其是在医疗基础设施仍在发展的新兴市场。

抑制因素和挑战：

市场面临诸多重大限制与挑战。监管障碍仍然是主要障碍，各国不同的法律体制使研发工作变得复杂。这种不一致会延缓医药品认证过程并增加合规成本。此外，围绕大麻衍生产品的偏见依然存在，影响着大众认知和投资者信心。这种偏见会阻碍潜在的合作关係和资金筹措机会。另外，人体内大麻素交互作用的复杂性需要精密的调查方法，这需要投入大量的时间和资源。智慧财产权问题也是一大挑战；现有专利的密集布局可能导致法律纠纷并阻碍创新。最后，市场也面临供应链限制，尤其是在采购高品质原料方面，这会影响生产计划和成本结构。总而言之，这些挑战阻碍了市场成长和更广泛的接受度。

目录

第一章执行摘要

第二章 市集亮点

第三章 市场动态

  • 宏观经济分析
  • 市场趋势
  • 市场驱动因素
  • 市场机会
  • 市场限制因素
  • 复合年均成长率：成长分析
  • 影响分析
  • 新兴市场
  • 技术蓝图
  • 战略框架

第四章：细分市场分析

  • 市场规模及预测：依类型
    • 合成大麻素
    • 天然大麻素
  • 市场规模及预测：依产品划分
    • 大麻二酚（CBD）
    • 四氢大麻酚（THC）
    • 大麻酚（CBG）
    • 大麻酚（CBN）
    • 大麻铬（CBC）
  • 市场规模及预测：依服务划分
    • 临床前研究
    • 临床试验
    • 监理咨询
    • 药物製剂
  • 市场规模及预测：依技术划分
    • 高效液相层析（HPLC）
    • 气相层析法（GC）
    • 质谱（MS）
    • 核磁共振（NMR）
  • 市场规模及预测：依应用领域划分
    • 疼痛管理
    • 神经系统疾病
    • 肿瘤学
    • 精神疾病
  • 市场规模及预测：依类型
    • 药片
    • 胶囊
    • 油
    • 奶油
    • 吸入器
  • 市场规模及预测：依最终用户划分
    • 製药公司
    • 研究机构
    • 受託研究机构
  • 市场规模及预测：依阶段划分
    • 药物发现
    • 临床前
    • 第一阶段
    • 第二阶段
    • 第三阶段
  • 市场规模及预测：按模式
    • 内部开发
    • 外包
  • 市场规模及预测：依功能划分
    • 缓解疼痛
    • 消炎（药）
    • 抗惊厥药
    • 神经保护

第五章 区域分析

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 拉丁美洲
    • 巴西
    • 阿根廷
    • 其他拉丁美洲地区
  • 亚太地区
    • 中国
    • 印度
    • 韩国
    • 日本
    • 澳洲
    • 台湾
    • 亚太其他地区
  • 欧洲
    • 德国
    • 法国
    • 英国
    • 西班牙
    • 义大利
    • 其他欧洲地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 南非
    • 撒哈拉以南非洲
    • 其他中东和非洲地区

第六章 市场策略

  • 供需差距分析
  • 贸易和物流限制
  • 价格、成本和利润率趋势
  • 市场渗透率
  • 消费者分析
  • 监管概述

第七章 竞争讯息

  • 市场定位
  • 市场占有率
  • 竞争基准
  • 主要企业的策略

第八章：公司简介

  • GW Pharmaceuticals
  • Corbus Pharmaceuticals
  • Zynerba Pharmaceuticals
  • Cara Therapeutics
  • InMed Pharmaceuticals
  • Tetra Bio-Pharma
  • Kalytera Therapeutics
  • Axim Biotechnologies
  • Emerald Health Pharmaceuticals
  • Vitality Biopharma
  • RespireRx Pharmaceuticals
  • CannbioRx Life Sciences
  • Ananda Scientific
  • Cardiol Therapeutics
  • Skylight Health Group
  • Medipharm Labs
  • Avicanna
  • PharmaCielo
  • The Valens Company
  • Lexaria Bioscience

第九章 关于我们

简介目录
Product Code: GIS33062

Cannabinoid Based Drug Discovery And Development Market is anticipated to expand from $1.76 billion in 2024 to $2.28 billion by 2034, growing at a CAGR of approximately 2.6%. The Cannabinoid Based Drug Discovery And Development Market encompasses the research and creation of pharmaceuticals derived from cannabinoids, targeting various medical conditions. This market leverages advancements in biotechnology to explore therapeutic potentials of cannabis compounds, focusing on pain management, neurological disorders, and oncology. Regulatory shifts and increasing acceptance of cannabis-based treatments propel innovation, with a strong emphasis on clinical trials and safety assessments to meet stringent medical standards.

The Cannabinoid Based Drug Discovery And Development Market is experiencing robust growth, propelled by increased research into therapeutic applications. The pharmaceuticals segment is at the forefront, driven by rising interest in cannabinoid-based therapeutics for pain management and neurological disorders. Within this segment, synthetic cannabinoids are the top performers due to their controlled composition and predictable effects. Natural cannabinoids follow as the second highest performing sub-segment, reflecting a growing preference for plant-derived compounds. The research and development services segment also shows promising growth, with contract research organizations (CROs) playing a pivotal role in advancing cannabinoid research. Preclinical research services are leading, driven by the need for comprehensive safety and efficacy data. Clinical trials services are the second most dynamic sub-segment, supported by increased regulatory approvals for cannabinoid-based treatments. Investment in innovative delivery systems, such as nanotechnology and transdermal patches, further enhances market potential, indicating a lucrative trajectory for stakeholders.

Market Segmentation
TypeSynthetic Cannabinoids, Natural Cannabinoids
ProductCannabidiol (CBD), Tetrahydrocannabinol (THC), Cannabigerol (CBG), Cannabinol (CBN), Cannabichromene (CBC)
ServicesPreclinical Research, Clinical Trials, Regulatory Consulting, Drug Formulation
TechnologyHigh-Performance Liquid Chromatography (HPLC), Gas Chromatography (GC), Mass Spectrometry (MS), Nuclear Magnetic Resonance (NMR)
ApplicationPain Management, Neurological Disorders, Oncology, Psychiatric Disorders
FormTablets, Capsules, Oils, Creams, Inhalers
End UserPharmaceutical Companies, Research Institutes, Contract Research Organizations
StageDiscovery, Preclinical, Phase I, Phase II, Phase III
ModeIn-House, Outsourced
FunctionalityAnalgesic, Anti-inflammatory, Anti-convulsant, Neuroprotective

Market Snapshot:

The Cannabinoid Based Drug Discovery and Development Market is witnessing dynamic shifts in market share, pricing strategies, and new product launches. Companies are leveraging innovative formulations and strategic partnerships to enhance their market positions. Pricing strategies are increasingly competitive, reflecting the need to balance affordability with cutting-edge research and development costs. Emerging markets are seeing a surge in product launches as regulatory landscapes become more favorable, allowing for a wider distribution of cannabinoid-based therapeutics. This environment fosters a landscape ripe for growth and innovation. Competition in the market is intense, with key players vying for dominance through advanced research capabilities and diversified product portfolios. Regulatory influences play a critical role, with stringent guidelines in North America and Europe setting high standards for product approval and market entry. Benchmarking against competitors reveals a trend towards increased investment in clinical trials and patent acquisitions. The market is characterized by rapid technological advancements, making it imperative for companies to stay ahead in innovation and regulatory compliance to maintain competitive advantage.

Geographical Overview:

The cannabinoid-based drug discovery and development market is witnessing notable growth across various regions, each presenting unique opportunities. North America leads the charge, driven by progressive legalization policies and substantial investments in research and development. The region's robust pharmaceutical infrastructure and consumer acceptance further accelerate market expansion. Europe follows with strong regulatory support and a growing focus on cannabinoid therapeutics for chronic conditions. The region's commitment to innovation and clinical trials enhances its market potential. In the Asia Pacific, the market is burgeoning, propelled by increasing awareness and investments in cannabinoid research. Countries like Australia and China are emerging as key players, leveraging scientific advancements and supportive regulations. Latin America and the Middle East & Africa are nascent markets with promising prospects. In Latin America, countries like Colombia are capitalizing on favorable climates for cannabis cultivation. Meanwhile, the Middle East & Africa are gradually recognizing the medicinal potential of cannabinoids, driving future growth.

Key Trends and Drivers:

The Cannabinoid Based Drug Discovery And Development Market is experiencing robust growth due to evolving regulatory landscapes and increasing acceptance of cannabinoid-based therapeutics. Key trends include the rise in clinical trials exploring cannabinoids for a wide range of medical conditions, from chronic pain management to neurological disorders. The pharmaceutical industry is witnessing a surge in strategic partnerships and collaborations aimed at accelerating drug discovery and development processes. A significant driver is the growing awareness of cannabinoids' therapeutic potential, which is spurring investment in research and development. This is further bolstered by advancements in biotechnology and genomics, enabling more precise targeting and formulation of cannabinoid-based drugs. Legalization efforts across various regions are expanding market access and fueling demand for innovative treatments. Additionally, the increasing prevalence of chronic diseases and an aging population are intensifying the need for novel therapeutic options, positioning cannabinoids as a promising alternative. Opportunities abound for companies that can navigate the complex regulatory environment and deliver effective, safe, and compliant cannabinoid-based therapies. As the market matures, there is potential for substantial growth, particularly in emerging markets with evolving healthcare infrastructures.

Restraints and Challenges:

The cannabinoid-based drug discovery and development market faces several notable restraints and challenges. Regulatory hurdles remain a significant barrier, as varying legal frameworks across countries complicate research and development efforts. This inconsistency can delay drug approval processes and increase compliance costs. Additionally, the stigma surrounding cannabis-derived products persists, affecting public perception and investor confidence. This stigma can deter potential partnerships and funding opportunities. Furthermore, the complexity of cannabinoid interactions within the human body requires sophisticated research methodologies, demanding substantial investment in time and resources. Intellectual property issues also pose challenges, as the dense landscape of existing patents can lead to legal disputes and hinder innovation. Lastly, the market grapples with supply chain constraints, particularly in sourcing high-quality raw materials, which can impact production timelines and cost structures. These challenges collectively impede the market's growth and potential for broader acceptance.

Key Players:

GW Pharmaceuticals, Corbus Pharmaceuticals, Zynerba Pharmaceuticals, Cara Therapeutics, InMed Pharmaceuticals, Tetra Bio-Pharma, Kalytera Therapeutics, Axim Biotechnologies, Emerald Health Pharmaceuticals, Vitality Biopharma, RespireRx Pharmaceuticals, CannbioRx Life Sciences, Ananda Scientific, Cardiol Therapeutics, Skylight Health Group, Medipharm Labs, Avicanna, PharmaCielo, The Valens Company, Lexaria Bioscience

Research Scope:

  • Estimates and forecasts the overall market size across type, application, and region.
  • Provides detailed information and key takeaways on qualitative and quantitative trends, dynamics, business framework, competitive landscape, and company profiling.
  • Identifies factors influencing market growth and challenges, opportunities, drivers, and restraints.
  • Identifies factors that could limit company participation in international markets to help calibrate market share expectations and growth rates.
  • Evaluates key development strategies like acquisitions, product launches, mergers, collaborations, business expansions, agreements, partnerships, and R&D activities.
  • Analyzes smaller market segments strategically, focusing on their potential, growth patterns, and impact on the overall market.
  • Outlines the competitive landscape, assessing business and corporate strategies to monitor and dissect competitive advancements.

Our research scope provides comprehensive market data, insights, and analysis across a variety of critical areas. We cover Local Market Analysis, assessing consumer demographics, purchasing behaviors, and market size within specific regions to identify growth opportunities. Our Local Competition Review offers a detailed evaluation of competitors, including their strengths, weaknesses, and market positioning. We also conduct Local Regulatory Reviews to ensure businesses comply with relevant laws and regulations. Industry Analysis provides an in-depth look at market dynamics, key players, and trends. Additionally, we offer Cross-Segmental Analysis to identify synergies between different market segments, as well as Production-Consumption and Demand-Supply Analysis to optimize supply chain efficiency. Our Import-Export Analysis helps businesses navigate global trade environments by evaluating trade flows and policies. These insights empower clients to make informed strategic decisions, mitigate risks, and capitalize on market opportunities.

TABLE OF CONTENTS

1 Executive Summary

  • 1.1 Market Size and Forecast
  • 1.2 Market Overview
  • 1.3 Market Snapshot
  • 1.4 Regional Snapshot
  • 1.5 Strategic Recommendations
  • 1.6 Analyst Notes

2 Market Highlights

  • 2.1 Key Market Highlights by Type
  • 2.2 Key Market Highlights by Product
  • 2.3 Key Market Highlights by Services
  • 2.4 Key Market Highlights by Technology
  • 2.5 Key Market Highlights by Application
  • 2.6 Key Market Highlights by Form
  • 2.7 Key Market Highlights by End User
  • 2.8 Key Market Highlights by Stage
  • 2.9 Key Market Highlights by Mode
  • 2.10 Key Market Highlights by Functionality

3 Market Dynamics

  • 3.1 Macroeconomic Analysis
  • 3.2 Market Trends
  • 3.3 Market Drivers
  • 3.4 Market Opportunities
  • 3.5 Market Restraints
  • 3.6 CAGR Growth Analysis
  • 3.7 Impact Analysis
  • 3.8 Emerging Markets
  • 3.9 Technology Roadmap
  • 3.10 Strategic Frameworks
    • 3.10.1 PORTER's 5 Forces Model
    • 3.10.2 ANSOFF Matrix
    • 3.10.3 4P's Model
    • 3.10.4 PESTEL Analysis

4 Segment Analysis

  • 4.1 Market Size & Forecast by Type (2020-2035)
    • 4.1.1 Synthetic Cannabinoids
    • 4.1.2 Natural Cannabinoids
  • 4.2 Market Size & Forecast by Product (2020-2035)
    • 4.2.1 Cannabidiol (CBD)
    • 4.2.2 Tetrahydrocannabinol (THC)
    • 4.2.3 Cannabigerol (CBG)
    • 4.2.4 Cannabinol (CBN)
    • 4.2.5 Cannabichromene (CBC)
  • 4.3 Market Size & Forecast by Services (2020-2035)
    • 4.3.1 Preclinical Research
    • 4.3.2 Clinical Trials
    • 4.3.3 Regulatory Consulting
    • 4.3.4 Drug Formulation
  • 4.4 Market Size & Forecast by Technology (2020-2035)
    • 4.4.1 High-Performance Liquid Chromatography (HPLC)
    • 4.4.2 Gas Chromatography (GC)
    • 4.4.3 Mass Spectrometry (MS)
    • 4.4.4 Nuclear Magnetic Resonance (NMR)
  • 4.5 Market Size & Forecast by Application (2020-2035)
    • 4.5.1 Pain Management
    • 4.5.2 Neurological Disorders
    • 4.5.3 Oncology
    • 4.5.4 Psychiatric Disorders
  • 4.6 Market Size & Forecast by Form (2020-2035)
    • 4.6.1 Tablets
    • 4.6.2 Capsules
    • 4.6.3 Oils
    • 4.6.4 Creams
    • 4.6.5 Inhalers
  • 4.7 Market Size & Forecast by End User (2020-2035)
    • 4.7.1 Pharmaceutical Companies
    • 4.7.2 Research Institutes
    • 4.7.3 Contract Research Organizations
  • 4.8 Market Size & Forecast by Stage (2020-2035)
    • 4.8.1 Discovery
    • 4.8.2 Preclinical
    • 4.8.3 Phase I
    • 4.8.4 Phase II
    • 4.8.5 Phase III
  • 4.9 Market Size & Forecast by Mode (2020-2035)
    • 4.9.1 In-House
    • 4.9.2 Outsourced
  • 4.10 Market Size & Forecast by Functionality (2020-2035)
    • 4.10.1 Analgesic
    • 4.10.2 Anti-inflammatory
    • 4.10.3 Anti-convulsant
    • 4.10.4 Neuroprotective

5 Regional Analysis

  • 5.1 Global Market Overview
  • 5.2 North America Market Size (2020-2035)
    • 5.2.1 United States
      • 5.2.1.1 Type
      • 5.2.1.2 Product
      • 5.2.1.3 Services
      • 5.2.1.4 Technology
      • 5.2.1.5 Application
      • 5.2.1.6 Form
      • 5.2.1.7 End User
      • 5.2.1.8 Stage
      • 5.2.1.9 Mode
      • 5.2.1.10 Functionality
    • 5.2.2 Canada
      • 5.2.2.1 Type
      • 5.2.2.2 Product
      • 5.2.2.3 Services
      • 5.2.2.4 Technology
      • 5.2.2.5 Application
      • 5.2.2.6 Form
      • 5.2.2.7 End User
      • 5.2.2.8 Stage
      • 5.2.2.9 Mode
      • 5.2.2.10 Functionality
    • 5.2.3 Mexico
      • 5.2.3.1 Type
      • 5.2.3.2 Product
      • 5.2.3.3 Services
      • 5.2.3.4 Technology
      • 5.2.3.5 Application
      • 5.2.3.6 Form
      • 5.2.3.7 End User
      • 5.2.3.8 Stage
      • 5.2.3.9 Mode
      • 5.2.3.10 Functionality
  • 5.3 Latin America Market Size (2020-2035)
    • 5.3.1 Brazil
      • 5.3.1.1 Type
      • 5.3.1.2 Product
      • 5.3.1.3 Services
      • 5.3.1.4 Technology
      • 5.3.1.5 Application
      • 5.3.1.6 Form
      • 5.3.1.7 End User
      • 5.3.1.8 Stage
      • 5.3.1.9 Mode
      • 5.3.1.10 Functionality
    • 5.3.2 Argentina
      • 5.3.2.1 Type
      • 5.3.2.2 Product
      • 5.3.2.3 Services
      • 5.3.2.4 Technology
      • 5.3.2.5 Application
      • 5.3.2.6 Form
      • 5.3.2.7 End User
      • 5.3.2.8 Stage
      • 5.3.2.9 Mode
      • 5.3.2.10 Functionality
    • 5.3.3 Rest of Latin America
      • 5.3.3.1 Type
      • 5.3.3.2 Product
      • 5.3.3.3 Services
      • 5.3.3.4 Technology
      • 5.3.3.5 Application
      • 5.3.3.6 Form
      • 5.3.3.7 End User
      • 5.3.3.8 Stage
      • 5.3.3.9 Mode
      • 5.3.3.10 Functionality
  • 5.4 Asia-Pacific Market Size (2020-2035)
    • 5.4.1 China
      • 5.4.1.1 Type
      • 5.4.1.2 Product
      • 5.4.1.3 Services
      • 5.4.1.4 Technology
      • 5.4.1.5 Application
      • 5.4.1.6 Form
      • 5.4.1.7 End User
      • 5.4.1.8 Stage
      • 5.4.1.9 Mode
      • 5.4.1.10 Functionality
    • 5.4.2 India
      • 5.4.2.1 Type
      • 5.4.2.2 Product
      • 5.4.2.3 Services
      • 5.4.2.4 Technology
      • 5.4.2.5 Application
      • 5.4.2.6 Form
      • 5.4.2.7 End User
      • 5.4.2.8 Stage
      • 5.4.2.9 Mode
      • 5.4.2.10 Functionality
    • 5.4.3 South Korea
      • 5.4.3.1 Type
      • 5.4.3.2 Product
      • 5.4.3.3 Services
      • 5.4.3.4 Technology
      • 5.4.3.5 Application
      • 5.4.3.6 Form
      • 5.4.3.7 End User
      • 5.4.3.8 Stage
      • 5.4.3.9 Mode
      • 5.4.3.10 Functionality
    • 5.4.4 Japan
      • 5.4.4.1 Type
      • 5.4.4.2 Product
      • 5.4.4.3 Services
      • 5.4.4.4 Technology
      • 5.4.4.5 Application
      • 5.4.4.6 Form
      • 5.4.4.7 End User
      • 5.4.4.8 Stage
      • 5.4.4.9 Mode
      • 5.4.4.10 Functionality
    • 5.4.5 Australia
      • 5.4.5.1 Type
      • 5.4.5.2 Product
      • 5.4.5.3 Services
      • 5.4.5.4 Technology
      • 5.4.5.5 Application
      • 5.4.5.6 Form
      • 5.4.5.7 End User
      • 5.4.5.8 Stage
      • 5.4.5.9 Mode
      • 5.4.5.10 Functionality
    • 5.4.6 Taiwan
      • 5.4.6.1 Type
      • 5.4.6.2 Product
      • 5.4.6.3 Services
      • 5.4.6.4 Technology
      • 5.4.6.5 Application
      • 5.4.6.6 Form
      • 5.4.6.7 End User
      • 5.4.6.8 Stage
      • 5.4.6.9 Mode
      • 5.4.6.10 Functionality
    • 5.4.7 Rest of APAC
      • 5.4.7.1 Type
      • 5.4.7.2 Product
      • 5.4.7.3 Services
      • 5.4.7.4 Technology
      • 5.4.7.5 Application
      • 5.4.7.6 Form
      • 5.4.7.7 End User
      • 5.4.7.8 Stage
      • 5.4.7.9 Mode
      • 5.4.7.10 Functionality
  • 5.5 Europe Market Size (2020-2035)
    • 5.5.1 Germany
      • 5.5.1.1 Type
      • 5.5.1.2 Product
      • 5.5.1.3 Services
      • 5.5.1.4 Technology
      • 5.5.1.5 Application
      • 5.5.1.6 Form
      • 5.5.1.7 End User
      • 5.5.1.8 Stage
      • 5.5.1.9 Mode
      • 5.5.1.10 Functionality
    • 5.5.2 France
      • 5.5.2.1 Type
      • 5.5.2.2 Product
      • 5.5.2.3 Services
      • 5.5.2.4 Technology
      • 5.5.2.5 Application
      • 5.5.2.6 Form
      • 5.5.2.7 End User
      • 5.5.2.8 Stage
      • 5.5.2.9 Mode
      • 5.5.2.10 Functionality
    • 5.5.3 United Kingdom
      • 5.5.3.1 Type
      • 5.5.3.2 Product
      • 5.5.3.3 Services
      • 5.5.3.4 Technology
      • 5.5.3.5 Application
      • 5.5.3.6 Form
      • 5.5.3.7 End User
      • 5.5.3.8 Stage
      • 5.5.3.9 Mode
      • 5.5.3.10 Functionality
    • 5.5.4 Spain
      • 5.5.4.1 Type
      • 5.5.4.2 Product
      • 5.5.4.3 Services
      • 5.5.4.4 Technology
      • 5.5.4.5 Application
      • 5.5.4.6 Form
      • 5.5.4.7 End User
      • 5.5.4.8 Stage
      • 5.5.4.9 Mode
      • 5.5.4.10 Functionality
    • 5.5.5 Italy
      • 5.5.5.1 Type
      • 5.5.5.2 Product
      • 5.5.5.3 Services
      • 5.5.5.4 Technology
      • 5.5.5.5 Application
      • 5.5.5.6 Form
      • 5.5.5.7 End User
      • 5.5.5.8 Stage
      • 5.5.5.9 Mode
      • 5.5.5.10 Functionality
    • 5.5.6 Rest of Europe
      • 5.5.6.1 Type
      • 5.5.6.2 Product
      • 5.5.6.3 Services
      • 5.5.6.4 Technology
      • 5.5.6.5 Application
      • 5.5.6.6 Form
      • 5.5.6.7 End User
      • 5.5.6.8 Stage
      • 5.5.6.9 Mode
      • 5.5.6.10 Functionality
  • 5.6 Middle East & Africa Market Size (2020-2035)
    • 5.6.1 Saudi Arabia
      • 5.6.1.1 Type
      • 5.6.1.2 Product
      • 5.6.1.3 Services
      • 5.6.1.4 Technology
      • 5.6.1.5 Application
      • 5.6.1.6 Form
      • 5.6.1.7 End User
      • 5.6.1.8 Stage
      • 5.6.1.9 Mode
      • 5.6.1.10 Functionality
    • 5.6.2 United Arab Emirates
      • 5.6.2.1 Type
      • 5.6.2.2 Product
      • 5.6.2.3 Services
      • 5.6.2.4 Technology
      • 5.6.2.5 Application
      • 5.6.2.6 Form
      • 5.6.2.7 End User
      • 5.6.2.8 Stage
      • 5.6.2.9 Mode
      • 5.6.2.10 Functionality
    • 5.6.3 South Africa
      • 5.6.3.1 Type
      • 5.6.3.2 Product
      • 5.6.3.3 Services
      • 5.6.3.4 Technology
      • 5.6.3.5 Application
      • 5.6.3.6 Form
      • 5.6.3.7 End User
      • 5.6.3.8 Stage
      • 5.6.3.9 Mode
      • 5.6.3.10 Functionality
    • 5.6.4 Sub-Saharan Africa
      • 5.6.4.1 Type
      • 5.6.4.2 Product
      • 5.6.4.3 Services
      • 5.6.4.4 Technology
      • 5.6.4.5 Application
      • 5.6.4.6 Form
      • 5.6.4.7 End User
      • 5.6.4.8 Stage
      • 5.6.4.9 Mode
      • 5.6.4.10 Functionality
    • 5.6.5 Rest of MEA
      • 5.6.5.1 Type
      • 5.6.5.2 Product
      • 5.6.5.3 Services
      • 5.6.5.4 Technology
      • 5.6.5.5 Application
      • 5.6.5.6 Form
      • 5.6.5.7 End User
      • 5.6.5.8 Stage
      • 5.6.5.9 Mode
      • 5.6.5.10 Functionality

6 Market Strategy

  • 6.1 Demand-Supply Gap Analysis
  • 6.2 Trade & Logistics Constraints
  • 6.3 Price-Cost-Margin Trends
  • 6.4 Market Penetration
  • 6.5 Consumer Analysis
  • 6.6 Regulatory Snapshot

7 Competitive Intelligence

  • 7.1 Market Positioning
  • 7.2 Market Share
  • 7.3 Competition Benchmarking
  • 7.4 Top Company Strategies

8 Company Profiles

  • 8.1 GW Pharmaceuticals
    • 8.1.1 Overview
    • 8.1.2 Product Summary
    • 8.1.3 Financial Performance
    • 8.1.4 SWOT Analysis
  • 8.2 Corbus Pharmaceuticals
    • 8.2.1 Overview
    • 8.2.2 Product Summary
    • 8.2.3 Financial Performance
    • 8.2.4 SWOT Analysis
  • 8.3 Zynerba Pharmaceuticals
    • 8.3.1 Overview
    • 8.3.2 Product Summary
    • 8.3.3 Financial Performance
    • 8.3.4 SWOT Analysis
  • 8.4 Cara Therapeutics
    • 8.4.1 Overview
    • 8.4.2 Product Summary
    • 8.4.3 Financial Performance
    • 8.4.4 SWOT Analysis
  • 8.5 InMed Pharmaceuticals
    • 8.5.1 Overview
    • 8.5.2 Product Summary
    • 8.5.3 Financial Performance
    • 8.5.4 SWOT Analysis
  • 8.6 Tetra Bio-Pharma
    • 8.6.1 Overview
    • 8.6.2 Product Summary
    • 8.6.3 Financial Performance
    • 8.6.4 SWOT Analysis
  • 8.7 Kalytera Therapeutics
    • 8.7.1 Overview
    • 8.7.2 Product Summary
    • 8.7.3 Financial Performance
    • 8.7.4 SWOT Analysis
  • 8.8 Axim Biotechnologies
    • 8.8.1 Overview
    • 8.8.2 Product Summary
    • 8.8.3 Financial Performance
    • 8.8.4 SWOT Analysis
  • 8.9 Emerald Health Pharmaceuticals
    • 8.9.1 Overview
    • 8.9.2 Product Summary
    • 8.9.3 Financial Performance
    • 8.9.4 SWOT Analysis
  • 8.10 Vitality Biopharma
    • 8.10.1 Overview
    • 8.10.2 Product Summary
    • 8.10.3 Financial Performance
    • 8.10.4 SWOT Analysis
  • 8.11 RespireRx Pharmaceuticals
    • 8.11.1 Overview
    • 8.11.2 Product Summary
    • 8.11.3 Financial Performance
    • 8.11.4 SWOT Analysis
  • 8.12 CannbioRx Life Sciences
    • 8.12.1 Overview
    • 8.12.2 Product Summary
    • 8.12.3 Financial Performance
    • 8.12.4 SWOT Analysis
  • 8.13 Ananda Scientific
    • 8.13.1 Overview
    • 8.13.2 Product Summary
    • 8.13.3 Financial Performance
    • 8.13.4 SWOT Analysis
  • 8.14 Cardiol Therapeutics
    • 8.14.1 Overview
    • 8.14.2 Product Summary
    • 8.14.3 Financial Performance
    • 8.14.4 SWOT Analysis
  • 8.15 Skylight Health Group
    • 8.15.1 Overview
    • 8.15.2 Product Summary
    • 8.15.3 Financial Performance
    • 8.15.4 SWOT Analysis
  • 8.16 Medipharm Labs
    • 8.16.1 Overview
    • 8.16.2 Product Summary
    • 8.16.3 Financial Performance
    • 8.16.4 SWOT Analysis
  • 8.17 Avicanna
    • 8.17.1 Overview
    • 8.17.2 Product Summary
    • 8.17.3 Financial Performance
    • 8.17.4 SWOT Analysis
  • 8.18 PharmaCielo
    • 8.18.1 Overview
    • 8.18.2 Product Summary
    • 8.18.3 Financial Performance
    • 8.18.4 SWOT Analysis
  • 8.19 The Valens Company
    • 8.19.1 Overview
    • 8.19.2 Product Summary
    • 8.19.3 Financial Performance
    • 8.19.4 SWOT Analysis
  • 8.20 Lexaria Bioscience
    • 8.20.1 Overview
    • 8.20.2 Product Summary
    • 8.20.3 Financial Performance
    • 8.20.4 SWOT Analysis

9 About Us

  • 9.1 About Us
  • 9.2 Research Methodology
  • 9.3 Research Workflow
  • 9.4 Consulting Services
  • 9.5 Our Clients
  • 9.6 Client Testimonials
  • 9.7 Contact Us